Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 10.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 224,945 shares of the company’s stock after selling 26,817 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Krystal Biotech were worth $40,947,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Summit Trail Advisors LLC purchased a new stake in Krystal Biotech in the 3rd quarter valued at approximately $1,893,000. Swiss National Bank raised its holdings in shares of Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after acquiring an additional 2,900 shares during the last quarter. Sei Investments Co. lifted its position in shares of Krystal Biotech by 18.9% in the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after acquiring an additional 6,363 shares in the last quarter. Shaker Investments LLC OH acquired a new stake in shares of Krystal Biotech during the third quarter valued at $532,000. Finally, Amalgamated Bank increased its position in Krystal Biotech by 937.9% during the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock worth $1,391,000 after purchasing an additional 6,847 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Down 4.6 %

Shares of NASDAQ KRYS opened at $185.97 on Wednesday. The stock has a market capitalization of $5.35 billion, a PE ratio of 105.07 and a beta of 0.80. The firm has a fifty day moving average of $180.92 and a 200-day moving average of $184.26. Krystal Biotech, Inc. has a 52-week low of $100.98 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.67) earnings per share. Equities research analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. Stifel Nicolaus lifted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Citigroup upped their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $202.29.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).